AHRQ cost-effectiveness agenda
This article was originally published in The Gray Sheet
Executive Summary
Initial priority list should be directed toward prescription drug comparative clinical effectiveness in expectation of the Medicare Rx benefit, according to an 1April 23 Federal Register notice. The agency notes, however, that other "health care items and services" will be considered for the FY 2006 list. Device stakeholders have been monitoring the Agency for Healthcare Research & Quality closely to determine whether devices will be subject to cost-effectiveness research under the Medicare Modernization Act provision (2"The Gray Sheet" April 12, 2004, p. 10). Proposed research items must be received by May 7 and July 1 for the initial and FY 2006 lists, respectively...
You may also be interested in...
Device Industry Mindful Of AHRQ Cost-Effectiveness Agenda, Due June 8
The device industry will discuss with AHRQ the need to consider long-term costs of new technology underutilization as the agency develops its cost-effectiveness research agenda
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.